학술논문
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
Document Type
Article
Author
Kimball, A.B.; Jemec, G.B.E.; Alavi, A.; Reguiai, Z.; Gottlieb, A.B.; Bechara, F.G.; Paul, C.; Giamarellos Bourboulis, E.J.; Villani, A.P.; Schwinn, A.; Ruëff, F.; Pillay Ramaya, L.; Reich, A.; Lobo, I.; Sinclair, R.; Passeron, T.; Martorell, A.; Mendes-Bastos, P.; Kokolakis, G.; Becherel, P.-A.; Wozniak, M.B.; Field, C.; Martinez, A.L.; Uhlmann, L.; Passera, A.; Vandemeulebroecke, M.; Wei, X.; Keefe, D.; Martin, R.; Chen, L.; Ravichandran, S.; Muscianisi, E.
Source
In: The Lancet . (The Lancet, 4 March 2023, 401(10378):747-761)
Subject
Language
English
ISSN
1474547X
01406736
01406736